Myriad Genetics Inc (NASDAQ:MYGN) is a company that focuses on molecular diagnostic testing. These tests assist in assessing an individual's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence.

Over the past year, the insider transaction history at Myriad Genetics Inc shows a total of 11 insider sells and no insider buys. Dale Muzzey's recent transaction follows this trend of insider selling, with the insider having sold a total of 2,100 shares over the past year and purchased none.

On the day of the sale, shares of Myriad Genetics Inc were trading at $26.17. This pricing gives the company a market cap of approximately $2.40 billion. According to the GF Value, the intrinsic value estimate for Myriad Genetics Inc is $23.47 per share, making the stock modestly overvalued with a price-to-GF-Value ratio of 1.12.

The GF Value is calculated based on historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.

This insider sale might be of interest to current and potential investors, as it provides insight into the actions of key executives within Myriad Genetics Inc.